The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 4, 2007, Pages 766-785

  Nogueira, Joseph ^a   Weir, Matthew ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DYSLIPIDEMIA; HUMAN; KIDNEY DISEASE; PRACTICE GUIDELINE; REVIEW;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CLINICAL TRIALS; DYSLIPIDEMIAS; HUMANS; KIDNEY DISEASES; PRACTICE GUIDELINES;

EID: 34548819060     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04131206     Document Type: Review

References (223)

1. Herzog CA: How to manage the renal patient with coronary heart disease: The agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 14: 2556-2572, 2003
2. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 87: S24-S31, 2003
3. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment cff hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13: I80-I93, 1989
4. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998
5. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322: 1700-1707, 1990
6. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823-2828, 1986
7. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 40: 1069-1118, 1978
8. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365-374, 1984
9. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622, 1998
10. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245, 1987
11. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995
13. Hebert PR, Gaziano JM, Chan KS, Hermekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278: 313-321, 1997
14. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Seizer RH, Blankenhorn DH, Hodis HN: Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 93: 34-41, 1996
15. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JR, Gotto AM Jr: Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99: 736-743, 1999
16. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289-1298, 1990
17. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264: 3013-3017, 1990
18. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 80: 1125-1129, 1997
19. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91: 2528-2540, 1995
20. Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KR, Kreuzer J, Hausmann D, Beckmann S, Gross M: Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104: 387-392, 2001
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994
22. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 102: 21-27, 2000
23. Pedersen TR, WiLhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyorala K, Wedel H: Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86: 257-262, 2000
24. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435, 2005
25. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349-1357, 1998
26. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009, 1996
27. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583-1592, 2001
28. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-418, 1999
29. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM Jr: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann Intern Med 142: 95-104, 2005
30. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB: Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 92: 2419-2425, 1995
31. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282: 2340-2346, 1999
32. Marchioli R, Marfisi RM, Carinci F, Tognoni G: Meta-analysis, clinical trials, and transferability of research resuits into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 156: 1158-1172, 1996
33. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 102: 1893-1900, 2000
34. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504, 2004
35. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292: 1307-1316, 2004
36. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, van Veldhuisen DJ: Effect of fluvastatin on ischaemia following acute myocardial infarction: A randomized trial. Eur Heart J 23: 1931-1937, 2002
37. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study - A randomized controlled trial. JAMA 285: 1711-1718, 2001
38. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22, 2002
39. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278, 2005
40. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001
41. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239, 2004
42. A coronary primary prevention study of Scottish men aged 45-64 years: Trial design. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 45: 849-860, 1992
43. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002
44. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563, 2004
45. Cheung AK, Samak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58: 353-362, 2000
46. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 13: 1918-1927, 2002
47. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57: 327-335, 2002
48. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59: 407-414, 2001
49. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002
50. Beddhu S, Allen-Brady K, Cheung AK, Home BD, Bair T, Muhlestein JB, Anderson JL: Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 62: 1776-1783, 2002
51. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-152, 2000
52. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, Mendelssohn D, Tobe S, Singer J, Thompson C: Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 38: 1398-1407, 2001
53. Landray MJ, Thambyrajah J, McGlynn FJ, Jones HJ, Baigent C, Kendall MJ, Townend JN, Wheeler DC: Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 38: 537-546, 2001
54. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
55. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41: 736-741, 1992
56. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340: 319-323, 1992
57. UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2 (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 36: 1021-1029, 1993
58. Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 2: 1300-1304, 1986
59. Valmadrid CT, Klein R, Moss SE, Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160: 1093-1100, 2000
60. Bianchi S, Bigazzi R, Campese VM: Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 34: 973-995, 1999
61. Calvino J, Calvo C, Romero R, Gude F, Sanchez-Guisande D: Atherosclerosis profile and microalbuminuria in essential hypertension. Am J Kidney Dis 34: 996-1001, 1999
62. Roest M, Banga JD, Janssen WM, Grobbee DE, Sixma JJ, de Jong PE, de Zeeuw D, Der Schouw YT: Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 103: 3057-3061, 2001
63. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogweft B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001
64. Wachtell K, Olsen MH, Dahlof B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. J Hypertens 20: 405-412, 2002
65. Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM: Association of the insulin resistance syndrome and microalbuminuria among nondiabetic Native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 13: 1626-1634, 2002
66. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, Leonetti G, Nachev C, Petrie JC, Rodicio JL, Rosenfeld JJ, Sarti C, Staessen JA: Prognostic significance of renal function in elderly patients with isolated systolic hypertension: Results from the Syst-Eur trial. J Am Soc Nephrol 13: 2213-2222, 2002
67. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W: Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290: 353-359, 2003
68. Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, Saito S: High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: An angiographic examination. J Am Soc Nephrol 16: 1141-1148, 2005
69. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906, 1998
70. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
71. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27: 347-354, 1996
72. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34: 125-134, 1999
73. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR: Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 12: 724-728, 1997
74. Covic A, Goldsmith DJ, Georgescu G, Verming MC, Ackrill P: Echocardiographic findings in long-term, long-hour hemodialysis patients. Clin Nephrol 45: 104-110, 1996
75. Dahan M, Siohan P, Viron B, Michel C, Paillole C, Gourgon R, Mignon F: Relationship between left ventricular hypertrophy, myocardial contractility, and load conditions in hemodialysis patients: An echocardiographic study. Am J Kidney Dis 30: 780-785, 1997
76. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
77. Foley RN, Parfrey PS, Harnett JD, Kent GM, O'Dea R, Murray DC, Barre PE: Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 9: 267-276, 1998
78. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989
79. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5: 2024-2031, 1995
80. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11: 1277-1285, 1996
81. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458-482, 1990
82. Tschope W, Koch M, Thomas B, Ritz E: Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron 64: 354-358, 1993
83. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, Inaba M: Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl S117-S120, 2003
84. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
85. Healthy People 2010:2005 annual data report. Am J Kidney Dis 47: S33-S46, 2006
86. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61: 297-304, 2002
87. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37: 484-489, 2001
88. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, Konig P, Auinger M, Wiesholzer M, Andersson H, Dieplinger H: Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl S113-S116, 2003
89. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6: 110-120, 1995
90. Levine DM, Gordon BR: Lipoprotein(a) levels in patients receiving renal replacement therapy: Methodologic issues and clinical implications. Am J Kidney Dis 26: 162-169, 1995
91. Assmann G, Schulte H, Funke H, von Eckardstein A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19[Suppl M]: M8-M14, 1998
92. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81: 7B-12B, 1998
93. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group: K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41[Suppl 3]: I-IV, S1-S91, 2003
94. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161: 1413-1419, 2001
95. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, Krauss RM: Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 95: 2022-2026, 1997
96. Phillips NR, Waters D, Havel RJ: Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88: 2762-2770, 1993
97. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9: 1277-1284, 1998
98. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H: Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 131: 229-236, 1997
99. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 41: 1653-1661, 1992
100. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ: Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20: 189-197, 2000
101. Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE, Wallendszus KR, Wilson SS, Lawson A, Peto R: Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 18: 235-241, 1997
102. Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H: Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol 43: 268-277, 1995
103. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H: Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl 71: S134-S136, 1999
104. Rosenson RS, Stein JH: Lp(a) metabolism and approach to the patient with high Lp(a) levels. In: UpToDate, edited by Rose BD, Waltham, MA, UpToDate, 2005
105. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM: Interaction of recombinant apolipoprotein (a) and lipoprotein (a) with macrophages. J Clin Invest 87: 767-771, 1991
106. Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J: High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 16: 1794-1802, 2005
107. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86: 475-482, 1992
108. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45: 876-883, 1994
109. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39: 1213-1217, 2002
110. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A: Non-lipid-related effects of statins. Ann Med 32: 164-176, 2000
111. Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 12: 2597-2602, 1997
112. Erten Y, Ozturk MA, Oktar S, Pasaoglu H, Reis KA, Derici U, Elbeg S, Guz G, Bali M, Arinsoy T, Sindel S: Association between neopterin and carotid intima-media thickness in hemodialysis patients. Nephron Clin Pract 101: c134-c138, 2005
113. Grekas D, Economou H, Makedou A, Destanis E, Theodoridou A, Avdelidou A, Demitriadis A, Tourkantonis A: Association between hyperhomocysteinemia and ultrasonographic atherosclerotic indices of carotid arteries in chronic hemodialysis patients. Nephron Clin Pract 101: c180-c186, 2005
114. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701, 1974
115. Ansari A, Kaupke CJ, Vaziri ND; Miller R, Barbari A: Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs 16: 31-36, 1993
116. Ikram H, Lynn KL, Bailey RR, Little PJ: Cardiovascular changes in chronic hemodialysis patients. Kidney Int 24: 371-376, 1983
117. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
118. Afzali B, Goldsmith DJ: Vascular calcification in chronic kidney disease. In: UpToDate, edited by Rose BD, Waltham, MA, UpToDate, 2006
119. Afzali B, Goldsmith DJ: Biology of vascular calcification in renal failure. In: UpToDate, edited by Rose BD, Waltham, MA, UpToDate, 2006
120. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340: 115-126, 1999
121. Shinohara K, Shoji T, Tsujimoto Y, Kimoto E, Tahara H, Koyama H, Emoto M, Ishimura E, Miki T, Tabata T, Nishizawa Y: Arterial stiffness in predialysis patients with uremia. Kidney Int 65: 936-943, 2004
122. Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmarm J, Hoeks AP, Rahn Kid: Studies of the vessel wall properties in hemodialysis patients. Kidney Int 45: 1397-1400, 1994
123. Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM: Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 32: 570-574, 1998
124. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434-2439, 1999
125. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103: 987-992, 2001
126. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF Jr: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287: 1548-1555, 2002
127. Amann K, Neususs R, Ritz E, Irzyniec T, Wiest G, Mall G: Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 8: 409-417, 1995
128. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G: Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7: 667-675, 1996
129. Amann K, Wolf B, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, Ritz E: Aortic changes in experimental renal failure: Hyperplasia or hypertrophy of smooth muscle cells? Hypertension 29: 770-775, 1997
130. Tornig J, Gross ML, Simonaviciene A, Mall G, Ritz E, Amann K: Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J Am Soc Nephrol 10: 77-83, 1999
131. Andresen JH, Nielsen HE: Andresen JH, Nielsen HE: Extraskeletal calcification in chronic renal failure during hemodialysis and after renal transplantation (author's transl) [in German]. Klin Wochenschr 60: 199-205, 1982
132. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P: Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis. Nephron 77: 37-43, 1997
133. Kuzela DC, Huffer WE, Conger JD, Winter SD, Hammond WS: Soft tissue calcification in chronic dialysis patients. Am J Pathol 86: 403--424, 1977
134. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003
135. Meema HE, Oreopoulos DG, deVeber GA: Arterial calcifications in severe chronic renal disease and their relationship to dialysis treatment, renal transplant, and parathyroidectomy. Radiology 121: 315-321, 1976
136. Meema HE, Oreopoulos DG: Morphology, progression, and regression of arterial and periarterial calcifications in patients with end-stage renal disease. Radiology 158: 671-677, 1986
137. Meema HE, Oreopoulos DG, Rapoport A: Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 32: 388-394, 1987
138. Milliner DS, Zinsmeister AR, Lieberman E, Landing B: Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38: 931-936, 1990
139. Shioi A, Taniwaki H, Jono S, Okuno Y, Koyama H, Mori K, Nishizawa Y: Monckeberg's medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis 38: S47-S49, 2001
140. McCullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review. J Nephrol 17: 205-215, 2004
141. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
142. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
143. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow
144. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824, 2005
145. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
146. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647, 2002
147. Brown BG, Morse J, Zhao XQ, Cheung M, Marino E, Albers JJ: Electron-beam tomography coronary calcium scores are superior to Framingham risk variables for predicting the measured proximal stenosis burden. Am J Cardiol 88: 23E-26E, 2001
148. Chen LC, Ding PY, Chen JW, Wu MH, Liu JC, Lan GY, Chern MS, Chang CY, Chang MS: Coronary artery calcium determined by electron beam computed tomography for predicting angiographic coronary artery disease in moderate - to high-risk Chinese patients. Cardiology 95: 183-189, 2001
149. Jensen JM, Gerdes LU, Jensen HK, Christiansen TM, Brorholt-Petersen JU, Faergeman O: Association of coronary heart disease with age-adjusted aortocoronary calcification in patients with familial hypercholesterolaemia. J Intern Med 247: 479-484, 2000
150. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ: Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: A study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant 19: 2307-2312, 2004
151. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
152. Bild DE, Folsom AR, Lowe LP, Sidney S, Kiefe C, Westfall AO, Zheng ZJ, Rumberger J: Prevalence and correlates of coronary calcification in black and white young adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol 21: 852-857, 2001
153. Valdes AM, Wolfe ML, Tate HC, Gefter W, Rut A, Rader DJ: Association of traditional risk factors with coronary calcification in persons with a family history of premature coronary heart disease: The study of the inherited risk of coronary atherosclerosis. J Investig Med 49: 353--361, 2001
154. Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H, Fukiyama K: Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 38: 64-69, 2001
155. Kudoh Y, Iimura O: Study on the atherosclerosis mechanism in chronic hemodialysis. Jpn Circ J 51: 631-641, 1987
156. Bonifacio DL, Malineni K, Kadakia RA, Soman SS, Sandberg KR, McCullough PA: Coronary calcification and cardiac events after percutaneous intervention in dialysis patients. J Cardiovasc Risk 8: 133-137, 2001
157. Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E: An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 41: 203-211, 2003
158. Annuk M, Lind L, Linde T, Fellstrom B: Impaired endothelium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant 16: 302-306, 2001
159. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12: 2747-2752, 2001
160. Passauer J, Pistrosch F, Bussemaker E, Lassig G, Herbrig K, Gross P: Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 16: 959-965, 2005
161. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97: e53-e59, 2005
162. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128, 2001
163. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117, 2001
164. Anderstam B, Katzarski K, Bergstrom J: Serum levels of NG,NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 8: 1437-1442, 1997
165. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10: 594-600, 1999
166. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
167. Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon ES, Oh HY, Kim DK: Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24: 1246-1252, 2004
168. de Groot K, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H, Fliser D: Uremia causes endothelial progenitor cell deficiency. Kidney Int 66: 641-646, 2004
169. Eizawa T, Murakami Y, Matsui K, Takahashi M, Muroi K, Amemiya M, Takano R, Kusano E, Shimada K, Ikeda U: Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin 19: 627-633, 2003
170. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600, 2003 :
171. Koc M, Richards HB, Bihorac A, Ross EA, Schold JD, Segal MS: Circulating endothelial cells are associated with future vascular events in hemodialysis patients. Kidney Int 67: 1078-1083, 2005
172. Soler MJ, Martinez-Estrada OM, Puig-Mari JM, Marco-Feliu D, Oliveras A, Vila J, Mir M, Orfila A, Vilaro S, Lloveras J: Circulating endothelial progenitor cells after kidney transplantation. Am J Transplant 5: 2154-2159, 2005
173. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1-E7, 2001
174. Afzali B, Haydar AA, Vinen K, Goldsmith DJ: From Finland to fatland: Beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 15: 2161-2168, 2004
175. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84: 413-428, 1999
176. Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB: Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 62: 550-557, 2002
177. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002
178. Libby P, Aikawa M: Mechanisms of plaque stabilization with statins. Am J Cardiol 91: 4B-8B, 2003
179. Marz W, Koenig W: HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering? J Cardiovasc Risk 10: 169-179, 2003
180. Matthys E, Schurgers M, Lamberigts G, Lameire N, Vandecasteele N, Labeur C, Beisiegel U, Rosseneu M: Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients. Atherosclerosis 86: 183-192, 1991
181. Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I, Maeda A, Kimura K, Takahashi T, Kishino M, Tone Y, Otani H, Ogawa A, Maeda T, Yukawa S: Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int Suppl 71: S219-S221, 1999
182. Robson R, Collins J, Johnson R, Kitching R, Searle M, Walker R, Douglas J, Leary J, Whalley G, Sharpe N, MacMahon S: Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. J Nephrol 10: 33-40, 1997
183. Walker RJ, Sutherland WH, Walker HL, MacMahon S, Robson RA: Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrol Dial Transplant 12: 87-92, 1997
184. Wanner C, Horl WH, Luley CH, Wieland H: Effects of HMG-CoA reductase inhibitors in hypercholesterole.mic patients on hemodialysis. Kidney Int 39: 754-760, 1991
185. Navaneethan SD, Shrivastava R: HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev (4): CD004289, 2004
186. Holdaas H, Felistrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031, 2003
187. Fellstrom B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR: Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 66: 1549-1555, 2004
188. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
189. Asselbergs FW, Diercks GF, Hrilege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Grist WH: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110: 2809-2816, 2004
190. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns HS, Collins R, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC: First United Kingdom Heart and Renal Protection (UK-HARP-I) Study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473-484, 2005
191. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, Ball S, Baxter A, Blackwell L, Cairns HS, Carr S, Collins R, Kourellias K, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC: The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47: 385-395, 2006
192. Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int Suppl S207-S210, 2003
193. Fellstrom BC, Holdaas H, Jardine AG: Why do we need a statin trial in hemodialysis patients? Kidney Int Suppl S204-S206, 2003
194. Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W: Effect of rosuvastatin on outcomes in chronic haemodialysis patients: Design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 6: 9, 2005
195. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, Levin A, Masri B, Parekh R, Wanner C, Wheeler DC, Wilson PW: Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4[Suppl 7]: 13-53, 2004
196. Kasiske BL: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32: S142-S156, 1998
197. Angeles C, Lane BP, Miller F, Nord EP: Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: Biopsy evidence of tubular toxicity. Am J Kidney Dis 44: 543-550, 2004
198. Sica DA, Gehr TW: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: Considerations in the renal failure patient. Curr Opin Nephrol Hypertens 11: 123-133, 2002
199. Singhvi SM, Pan HY, Morrison RA, Willard DA: Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 29: 239-243, 1990
200. Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC: Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 37: 816-819, 1997
201. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V: Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 137: 1039-1046, 2002
202. Leblond FA, Giroux L, Villeneuve JP, Pichette V: Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 28: 1317-1320, 2000
203. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V: Dowuregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326-332, 2001
204. Pastemak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33: 2337-2341, 2002
205. Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schuler S, Jaross W: Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 6: 351-361, 2001
206. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U: Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62: 311-321, 1997
207. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33: 537-546, 2005
208. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274: 37161-37168, 1999
209. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304: 610-616, 2003
210. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH, Kuhlmann J: Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65: 251-261, 1999
211. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72: 685-691, 2002
212. Shitara Y, Hirano M, Sato H, Sugiyama Y: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/ OATP1BI:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastaffn and gemfibrozil. J Pharmacol Exp Ther 311: 228-236, 2004
213. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y: CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 4: 1514-1522, 2004
214. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD: Combined therapy with atorvastatin and calcineurin inhibitors: No interactions with tacrolimus. Am J Transplant 5: 2236-2243, 2005
215. Veau C, Leroy C, Banide H, Auchere D, Tardivel S, Farinotti R, Lacour B: Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant 16: 1607-1614, 2001
216. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA: Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 37: 1033-1035, 2005
217. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F: A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 6: 770-774, 2006
218. Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O: Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 6: 205-208, 2006
219. Langone AJ, Chuang P: Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 81: 804-807, 2006
220. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Maxwell SE, Kosoglou T, Murphy G, Gottesdiener K, Robson R, Paolini JF: Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 46: 328-336, 2006
221. Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ: Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 39: 1561-1565, 2005
222. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266, 2002
223. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 19: 1139-1147, 2001